Enzo Biochem, Inc. ENZ

Competitive advantage analysis · healthcare

Medical Devices & Diagnostics
Overall moat score
—
Insufficient data

Ranked against 61 peers in Diagnostics & Research

The dashed ring is the peer median. Defense scores are percentile ranks against peers, so 50 is roughly the typical company in this group.

Upgrade to unlock the signals and evidence behind each defense.

Premium access

Unlock full defense analysis

Get key signals, strengths, and risks for every moat dimension.

Upgrade to Premium Unlock all moat defenses and evidence.

Pricing Power & Consumable Moat

Insufficient Data
—
Premium

Signals, strengths and risks for Pricing Power & Consumable Moat

Premium

Signals, strengths and risks for R&D Pipeline & Capital Returns

Premium

Signals, strengths and risks for FCF Quality & Cash Conversion

Premium

Signals, strengths and risks for Commercial Execution

Premium

Signals, strengths and risks for Capital Structure & Resilience

Premium

Signals, strengths and risks for Growth Durability

Where ENZ ranks in Diagnostics & Research

Enzo Biochem, Inc. ranks #61 of 62 scored companies in Diagnostics & Research by moat score — the top 98%. The widest moat in the group is IDEXX Laboratories, Inc. (IDXX) at 78/100.

# Company Moat score Rating
54 Aclaris Therapeutics, Inc. ACRS 18/100 Weak
55 ProPhase Labs, Inc. PRPH 17/100 Weak
56 iSpecimen Inc. ISPC 11/100 Weak
57 T2 Biosystems, Inc. TTOO 6/100 Weak
58 Applied DNA Sciences, Inc. APDN 0/100 Weak
59 Aspira Women's Health Inc. AWH 0/100 Weak
60 Check-Cap Ltd. CHEK 0/100 Weak
61 Enzo Biochem, Inc. ENZ 0/100 Weak
62 OncoCyte Corporation OCX 0/100 Weak

See every Medical Devices & Diagnostics company ranked by moat score →

How ENZ scores on the Medical Devices & Diagnostics defenses

Pricing Power & Consumable Moat

Not measurable · 25% of the moat score

In MedTech, pricing power is rarely about the machine — it is about what the machine consumes.

R&D Pipeline & Capital Returns

Not measurable · 20% of the moat score

Research spending is how a device company keeps its installed base current, but spending alone proves nothing.

FCF Quality & Cash Conversion

Not measurable · 20% of the moat score

MedTech companies grow by acquisition, and the resulting intangible amortisation depresses reported earnings without consuming any cash.

Commercial Execution

Not measurable · 15% of the moat score

Devices are sold into hospitals and labs through committees, tenders and long qualification cycles, which makes the sales organisation expensive and hard to replicate.

Capital Structure & Resilience

Not measurable · 12% of the moat score

Serial acquirers carry debt, and the question is whether the cash flows underneath it are dependable enough to service it through a downturn.

Growth Durability

Not measurable · 8% of the moat score

Growth durability separates an expanding installed base from a good product cycle.

How each Medical Devices & Diagnostics defense is measured, in full →

Understanding ENZ's moat

What is Enzo Biochem, Inc.'s moat score?

Enzo Biochem, Inc. (ENZ) scores 0 out of 100 on the StatsAlpha Moat Map, which rates its competitive advantage as weak. It ranks #61 of 62 scored companies in Diagnostics & Research, the top 98%. The score is a weighted composite of 6 competitive defenses, each measured against industry peers of 61 companies in Diagnostics & Research.

How does Enzo Biochem, Inc. compare with other Diagnostics & Research companies?

Enzo Biochem, Inc. ranks #61 of 62 scored companies in Diagnostics & Research by moat score. The widest moat in Diagnostics & Research is IDEXX Laboratories, Inc. (IDXX) at 78/100. The companies ranked closest are Check-Cap Ltd. (CHEK) at 0 just above it and OncoCyte Corporation (OCX) at 0 just below it.

How is the moat score calculated?

Each company is scored with an industry-specific template — Medical Devices & Diagnostics in this case, chosen because the defenses that matter to a bank are not the ones that matter to a software company. Every defense combines several financial signals, and each signal is measured as a percentile against a peer group of 61 companies in Diagnostics & Research. The defenses are then weighted to produce the overall score out of 100.

Why is Enzo Biochem, Inc. scored with the Medical Devices & Diagnostics template?

Medical device and diagnostics companies place an instrument once and then sell the consumables, reagents and service that instrument needs for the next decade. The economics are a razor-and-blade model wrapped in regulatory approval and clinician habit, so the MedTech template scores the durability of that installed base rather than the size of any single product launch.

Which competitive defenses are measured for Enzo Biochem, Inc.?

The Medical Devices & Diagnostics template measures 6 defenses, and ENZ scores: Pricing Power & Consumable Moat (not measurable), R&D Pipeline & Capital Returns (not measurable), FCF Quality & Cash Conversion (not measurable), Commercial Execution (not measurable), Capital Structure & Resilience (not measurable), Growth Durability (not measurable). Each is scored independently as a percentile against peers, so a company can be strong on one and weak on another — the overall score reflects how those defenses are weighted for this industry.

Send Feedback
Please select a category.
0/1000